2021
DOI: 10.1038/s41467-021-26469-4
|View full text |Cite
|
Sign up to set email alerts
|

Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells

Abstract: Class 2 CRISPR systems are exceptionally diverse, nevertheless, all share a single effector protein that contains a conserved RuvC-like nuclease domain. Interestingly, the size of these CRISPR-associated (Cas) nucleases ranges from >1000 amino acids (aa) for Cas9/Cas12a to as small as 400-600 aa for Cas12f. For in vivo genome editing applications, compact RNA-guided nucleases are desirable and would streamline cellular delivery approaches. Although miniature Cas12f effectors have been shown to cleave double… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
49
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 63 publications
(50 citation statements)
references
References 49 publications
1
49
0
Order By: Relevance
“…Success here is leading to a new class of therapeutic interventions ( 15–17 ) to confront diseases ‘ upstream ’ by targeting their genomic origin, with precise molecular destruction of pathogenic RNAs before they translate into the disease. Over recent decades, powerful and versatile sequence-specific interventions, such as siRNAs ( 18–24 ) CRISPR ( 25–27 ) and antisense oligonucleotides (ASOs) ( 28–41 ) have emerged for genome editing and for manipulation of gene expression, reliant upon the precision of Watson-Crick base-pairing between short RNA or DNA guide sequences and target nucleic acids. Recent advances have enhanced their serum stability, safety profiles and improved cell-targeting capabilities ( 22–26 , 31 ).…”
Section: Introductionmentioning
confidence: 99%
“…Success here is leading to a new class of therapeutic interventions ( 15–17 ) to confront diseases ‘ upstream ’ by targeting their genomic origin, with precise molecular destruction of pathogenic RNAs before they translate into the disease. Over recent decades, powerful and versatile sequence-specific interventions, such as siRNAs ( 18–24 ) CRISPR ( 25–27 ) and antisense oligonucleotides (ASOs) ( 28–41 ) have emerged for genome editing and for manipulation of gene expression, reliant upon the precision of Watson-Crick base-pairing between short RNA or DNA guide sequences and target nucleic acids. Recent advances have enhanced their serum stability, safety profiles and improved cell-targeting capabilities ( 22–26 , 31 ).…”
Section: Introductionmentioning
confidence: 99%
“…Cas12g was characterized by RNA-guided collateral ribonuclease and single-strand deoxyribonuclease activities ( Yan et al, 2019 ). Cas12f (also known as Cas14) nucleases cleave single- and dsDNA targets triggered by a 5′ T- or C-rich PAM sequence ( Harrington et al, 2018 ; Karvelis et al, 2020 ; Bigelyte et al, 2021 ; Xu X. et al, 2021 ; Takeda et al, 2021 ).…”
Section: Crispr-based Biosensing Techniquesmentioning
confidence: 99%
“…Obligated mobile element-guided activity (OMEGA) is another class of transposon-encoded RGENs with a reduced size (∼400 amino acids) ( Altae-Tran et al, 2021 ). Miniature CRISPR associated RGENs such as Cas12f are also being explored for gene editing capability and engineered for improved efficiency ( Bigelyte et al, 2021 ; Xu et al, 2021 ). The discovery and optimization of these smaller genome editing tools may facilitate delivery with germline infecting PSVs such as TRV or BSMV.…”
Section: Virus Induced Genome Editingmentioning
confidence: 99%